DigestRedComo funciona
Red
/
Empresas
Bi
No verificado

Biogen Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

74 Comunicados de prensa

Ver todos los comunicados de prensa
17/09/2026
Biotecnología
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
03/09/2026
Biotecnología
Gestión empresarial/Administración de Empresas
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
01/09/2026
Biotecnología
Medicina Salud Bienestar
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
06/08/2026
Biotecnología
Medicina Salud Bienestar
Biogen Completes Acquisition of RayThera Inc.
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
15/07/2026
Biotecnología
Biogen Appoints Michael J. Parini as Chief Legal Officer
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
29/06/2026
Biotecnología
Medicina Salud Bienestar
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
17/06/2026
Biotecnología
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
04/06/2026
Biotecnología
Anuncios breves
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
03/06/2026
Biotecnología
Medicina Salud Bienestar
Anuncios breves
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
14/05/2026
Biotecnología
Medicina Salud Bienestar
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0